| Active, not recruiting | 3 | 430 | Europe, Canada, US, RoW | Pelabresib, Ruxolitinib, Placebo | Constellation Pharmaceuticals | Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis | 08/23 | 12/27 | | |
Predictor2, NCT03887156: Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft |
|
|
| Recruiting | 2/3 | 227 | Europe | Ex vivo capacities of CD4neg INkT expansion of the peripheral blood donor with the Predictor test | Assistance Publique - Hôpitaux de Paris, SATT, SNC Graft Versus Host Disease, Imagine Institute, Axonal-Biostatem, CERBA laboratory | Acute Myeloid Leukemia in Remission, Lymphoma in Remission, Non-progressive Myeloproliferative Syndrome, Myelodysplasia With Stable Blasts is Cell Number and < 10% of Blastocysts, Acute Leukemia Biphenotypic in Remission, Acute Lymphoblastic Leukemia | 03/23 | 03/23 | | |
NCT02629692 / 2016-001754-18: Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies |
|
|
| Active, not recruiting | 1/2 | 122 | Europe, US, RoW | Vodobatinib (K0706) capsules | Sun Pharma Advanced Research Company Limited | Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C) | 08/26 | 08/26 | | |
